RARE falls to fresh 52-week low as FDA decision nears
Ultragenyx Pharmaceutical shares slipped and hit a fresh 52-week low ahead of an FDA decision this week on UX111, a one-time gene therapy for Sanfilippo syndrome type A. The stock fell as much as 1.45% intraday.
Shares of Ultragenyx Pharmaceutical (RARE) fell on Wednesday to a fresh 52-week low, with investors awaiting a U.S. Food and Drug Administration (FDA) decision due this week on UX111, a one-time gene therapy for Sanfilippo syndrome type A. The stock dropped as much as 1.45% intraday.